STOCK TITAN

Fortrea Holdings Inc. - $FTRE STOCK NEWS

Welcome to our dedicated page for Fortrea Holdings news (Ticker: $FTRE), a resource for investors and traders seeking the latest updates and insights on Fortrea Holdings stock.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Fortrea Holdings's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Fortrea Holdings's position in the market.

Rhea-AI Summary

Fortrea, a leading global contract research organization (CRO), has rescheduled the release of its first quarter 2024 financial results to May 13, 2024. This delay is due to ongoing accounting and discontinued operations matters following a recent asset divestiture agreement. The company will host a conference call on the release date to discuss the financial results and conduct a Q&A session.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.86%
Tags
-
Rhea-AI Summary
Fortrea (FTRE) will release its first quarter 2024 financial results on May 7, 2024, followed by a conference call for a review and Q&A session. Participants can register online to join the call and access the earnings webcast link.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.61%
Tags
-
Rhea-AI Summary
Fortrea (Nasdaq: FTRE) announces the proposed divestiture of Endpoint Clinical and Fortrea Patient Access businesses to Arsenal Capital Partners, streamlining its focus as a contract research organization. The divestiture aims to enhance investment in technology and operations, positioning the remaining business for growth. The transaction is expected to close in the second quarter of 2024, subject to regulatory approvals.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.14%
Tags
none
Rhea-AI Summary
Fortrea (FTRE) reports strong financial results for Q4 2023 and full year 2023, with revenues of $775.4 million and $3,109.0 million, respectively. The company achieved a fourth-quarter book-to-bill ratio of 1.30x, showing growth and a focus on clinical services. Despite a GAAP net loss, Fortrea remains optimistic about its future performance and strategic initiatives.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.14%
Tags
-
Rhea-AI Summary
Fortrea (Nasdaq: FTRE) expands its non-commercial specialty pharmacy, FortreaRx™, in Lake Mary, Florida, offering advanced patient access solutions across the U.S. The facility doubles its operational space, providing ambient and cold-chain distribution capabilities. Since 2008, Fortrea has been a pioneer in non-commercial specialty pharmacy services, focusing on free-goods products for qualified patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.77%
Tags
none
-
Rhea-AI Summary
Fortrea (FTRE) to present at Barclays 26th Annual Global Healthcare Conference. Chairman and CEO, Tom Pike, and CFO, Jill McConnell, to speak on March 12, 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.62%
Tags
conferences
Rhea-AI Summary
Fortrea (Nasdaq: FTRE) will release its Q4 and full year 2023 financial results on March 11, 2024. The company will host a conference call to review the results and conduct a Q&A session. Participants can register online to join the call and access the earnings webcast link. A replay will be available on the company's Investor Relations website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.24%
Tags
-
Rhea-AI Summary
Fortrea (Nasdaq: FTRE) partners with Veeva Systems Inc. and Advarra to provide an integrated patient- and site-centric solution that streamlines the clinical trial experience. The partnership aims to address the challenges faced by clinical research investigator sites and sponsors by offering a unified technology solution that eases the administrative burden for patients and sites, increasing the accessibility of clinical trials for the public.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.02%
Tags
partnership clinical trial
-
Rhea-AI Summary
Fortrea (Nasdaq: FTRE) previews key updates at the 42nd Annual J.P. Morgan Healthcare Conference, showcasing strong progress in establishing infrastructure, winning new business, and conducting independent expert review of clinical trials.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.19%
Tags
none
Rhea-AI Summary
Cognizant (CTSH) to Help Fortrea (FTRE) Deploy Secure Digital Ecosystem for Faster Patient Treatment Delivery
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.11%
Tags
none
Fortrea Holdings Inc.

Nasdaq:FTRE

FTRE Rankings

FTRE Stock Data

3.26B
76.62M
0.13%
100.59%
5.2%
Testing Laboratories
Professional, Scientific, and Technical Services
Link
United States of America
DURHAM